Amgen AMGN Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| Aranesp | $1.36B+2.0% | $1.39B+3.5% | $1.36B+0.8% | $1.34B+0.4% | $1.33B-1.7% | |
| BLINCYTO | $1.6B+19.5% | $1.56B+28.2% | $1.53B+41.9% | $1.46B+50.9% | $1.34B+47.3% | |
| ENBREL | $2.04B-37.5% | $2.23B-32.9% | $2.71B-18.3% | $2.95B-16.2% | $3.26B-11.6% | |
| EVENITY | $2.22B+33.5% | $2.1B+34.4% | $1.93B+33.2% | $1.79B+31.8% | $1.66B+33.3% | |
| KRYSTEXXA | $1.36B+14.6% | $1.34B+13.1% | $1.25B+12.6% | $1.24B+54.9% | $1.19B+134% | |
| KYPROLIS | $1.42B-2.3% | $1.41B-6.1% | $1.43B-3.2% | $1.45B0.0% | $1.45B+2.1% | |
| Nplate | $1.62B+11.8% | $1.52B+4.7% | $1.48B-1.9% | $1.48B+0.5% | $1.45B+1.4% | |
| Otezla | $2.26B+4.1% | $2.27B+6.5% | $2.26B+6.2% | $2.24B+5.1% | $2.17B-1.0% | |
| Other products | $7.14B+24.6% | $7.09B+26.0% | $6.59B+21.1% | $6.1B+20.0% | $5.73B+17.1% | |
| Prolia | $4.04B-9.7% | $4.41B+0.9% | $4.53B+4.8% | $4.43B+4.1% | $4.47B+8.6% | |
| TEPEZZA | $2.01B+11.3% | $1.9B+2.8% | $1.91B+3.6% | $1.83B+35.8% | $1.81B+107% | |
| TEZSPIRE | $1.54B+41.7% | $1.48B+52.1% | $1.3B+52.4% | $1.19B+60.0% | $1.08B+68.3% | |
| Vectibix | $1.2B+12.2% | $1.18B+12.4% | $1.1B+5.0% | $1.1B+7.8% | $1.07B+6.7% | |
| XGEVA | $1.93B-13.5% | $2.08B-6.3% | $2.2B+0.3% | $2.2B+1.4% | $2.23B+4.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amgen break its business down?
- Amgen (AMGN) reports total revenues by product across 18 parts — Aranesp, BLINCYTO, ENBREL, EVENITY and IMDELLTRA/IMDYLLTRA. Each is extracted from the segment footnotes and tracked over time.
- Where does Amgen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amgen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
